GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025
GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025
GRI生物亮点GRI-0621潜在降低特发性肺纤维化炎症和肝纤维化，在AFDD峰会上呈现积极的临床前数据，并预计2025年Q2发布第2阶段数据。
GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025
GRI Bio 强调了 GRI-0621 减少特发性肺纤维化炎症和肝纤维化的潜力，在 AFDD 峰会上公布了积极的临床前数据，第二阶段的头条数据预计将于 2025 年第二季度公布
资讯热榜
更新时间